Form 4: Elanco EVP Bettington Boosts Equity Holdings

Elanco Animal Health Inc.'s Executive Vice President, Timothy J. Bettington, reported significant equity grants and option awards, alongside a tax-related stock disposition, under a pre-arranged trading plan.

Summary

• Timothy J. Bettington, Executive Vice President, Center of Strategic Growth at Elanco Animal Health Inc., reported several transactions on March 1, 2026.
• Acquired 46,322 shares of common stock at a price of $0.
• Disposed of 18,098 shares of common stock at $26.4, likely for tax withholding purposes.
• Received a grant of 9,470 restricted stock units (RSUs) at $0, which will vest in three equal annual installments starting March 1, 2027.
• Received a grant of 19,350 employee stock options with an exercise price of $24.6, also vesting in three equal annual installments starting March 1, 2027, and expiring on March 1, 2036.
• Following these transactions, Bettington beneficially owns 147,956 shares of common stock and 19,350 employee stock options.
• All reported transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it reflects ongoing executive compensation and retention efforts through equity grants, aligning management's interests with long-term company performance. The disposition is likely tax-related and not a negative signal regarding the company's prospects.

Positives

• Timothy J. Bettington received a grant of 46,322 shares of common stock at no cost, increasing his direct equity stake.
• Timothy J. Bettington received a grant of 9,470 restricted stock units (RSUs) at no cost, aligning his long-term interests with shareholder value.
• Timothy J. Bettington was granted 19,350 employee stock options with an exercise price of $24.6, providing future upside potential tied to the company's stock performance.
• The transactions were executed under a Rule 10b5-1(c) plan, indicating pre-planned and systematic equity management by the executive.

Negatives

• Timothy J. Bettington disposed of 18,098 shares of common stock at $26.4, which represents a reduction in direct share ownership, although this is typically for tax withholding related to vesting events.

Future Outlook

The vesting schedules for the granted restricted stock units and employee stock options extend through March 1, 2029, indicating a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that executive equity grants and option awards are standard practices in the animal health industry, aligning executive incentives with long-term company performance and shareholder interests. The use of a 10b5-1 plan is also a common practice for executives to manage their equity holdings systematically and avoid accusations of insider trading.

Stakeholder Impact

• Shareholders: The equity grants align executive incentives with shareholder interests, potentially fostering long-term value creation.
• Employees: Reflects standard executive compensation practices, which can influence overall compensation philosophy within the company.

Next Steps

• One-third of the restricted stock units and employee stock options will vest on March 1, 2027.
• Another one-third of the restricted stock units and employee stock options will vest on March 1, 2028.
• The remaining portion of the restricted stock units and employee stock options will vest on March 1, 2029.
• Employee stock options will expire on March 1, 2036.

Key Dates

Recommendation

The filing details routine executive compensation and tax-related transactions under a pre-arranged plan. While the grants align executive interests with long-term company performance, these transactions alone do not provide sufficient new information to warrant a change in investment recommendation. Investors should continue to monitor broader company performance and market conditions.

Keywords

Elanco Animal Health, ELAN, Timothy J. Bettington, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Equity Grant, Executive Compensation, 10b5-1 Plan